Target intelligence / Profile preview

WD repeat domain phosphoinositide-interacting protein 2 (WIPI2)

Target
WIPI2
Molecular classification
WD40 repeat protein, Autophagy regulatory protein, PROPPIN protein (β-propellers that bind polyphosphoinositides), Cytosolic scaffold protein (not a G protein-coupled receptor, ion channel, enzyme, or classical receptor)
01

Overview

WD repeat domain phosphoinositide-interacting protein 2 (WIPI2) is a cytosolic scaffolding protein containing seven WD40 repeats that assemble into a β-propeller structure. WIPI2 binds phosphatidylinositol 3-phosphate (PI(3)P) via its conserved FRRG motif and is a critical effector recruited to the nascent autophagosome in response to autophagy induction. At the phagophore, WIPI2 interacts with the ATG16L1–ATG12–ATG5 complex, enabling LC3 lipidation and autophagosome maturation. Loss or mutation of WIPI2 disrupts autophagosome formation and is implicated in developmental disorders, defective pathogen clearance, and may contribute to cancer and neurodegeneration. WIPI2 does not act as a receptor, enzyme, or ion channel, but as a key scaffold and organizer within the autophagy pathway.

Other names
WIPI2ATG18BWIPI-2Atg21CGI-50WD repeat domain phosphoinositide-interacting protein 2WD40 repeat protein interacting with phosphoinositides 2WIPI49-like protein 2IDDSSAFLJ12979FLJ14217FLJ42984DKFZP434J154DKFZp686P02188
02

Mechanism of action

Drugs targeting WIPI2 would theoretically act by: - Modulating autophagosome biogenesis - Enhancing or inhibiting ATG16L1–LC3 recruitment to autophagosome membranes - Inhibition by promoting WIPI2 ubiquitination and proteasomal degradation (e.g. CUL4-RING E3 ligase–mediated action during mitosis)

03

Biological functions

Autophagosome formationProtein-protein interaction scaffoldPhosphoinositide bindingRecruitment of ATG16L1–ATG12–ATG5 complexLC3 lipidation initiationClearance of intracellular pathogensMaintenance of cellular homeostasis (esp. during nutrient deprivation)
04

Disease associations

Neurodegenerative disease (autophagy decline, age-related misregulation)Cancer (regulation of autophagy in tumor cells)Intellectual developmental disorders (mutations result in syndromic disease)Infection (required for autophagic clearance of pathogens)
05

Safety considerations

Therapeutic modulation of WIPI2 may risk impairing normal autophagic flux, resulting in accumulation of damaged organelles and proteins, cellular stress, and neurodegenerationSystemic autophagy inhibition may affect immune response and increase susceptibility to infections and tumor progression
06

Interacting drugs

No approved drugs directly targeting WIPI2 are reported as of September 2025. Experimental autophagy modulators may indirectly impact WIPI2 function (such as PI3 kinase inhibitors or autophagy inhibitors like chloroquine), but WIPI2 itself is not a direct molecular target for any marketed pharmacologic agent
07

Biomarkers

WIPI2 puncta (marker of autophagosome formation, used in microscopy for autophagy flux)LC3 lipidation (readout of WIPI2-dependent autophagic machinery)

Beyond the preview

Go deeper on WD repeat domain phosphoinositide-interacting protein 2 (WIPI2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD repeat domain phosphoinositide-interacting protein 2 (WIPI2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call